Portfolio overview as at 30 April 2012
Allocation of assets
|
|
in CHF per share |
in % |
|---|---|---|
|
Private companies |
21.63 |
35.2 |
|
Specialised venture capital funds |
8.40 |
13.7 |
|
Public companies |
23.17 |
37.7 |
|
Other assets |
4.32 |
7.0 |
|
Cash and cash equivalents |
4.00 |
6.5 |
|
Total assets |
61.52 |
100.00 |
|
|
|
|
|
/. Liabilities |
-0.97 |
|
|
Total net assets |
60.55 |
|
Currency allocation
|
Assets held in |
in CHF per share |
in % |
|---|---|---|
|
USD |
35.52 |
57.7 |
|
EUR |
6.37 |
10.4 |
|
CHF |
17.51 |
28.5 |
|
Others (SEK, GBP, DKK) |
2.12 |
3.5 |
|
Total assets |
51.52 |
100.00 |
|
|
|
|
|
/. Liabilities due in |
|
|
|
CHF |
-0.27 |
|
|
USD |
-0.70 |
|
|
Total net assets |
60.55 |
|
Share Price
SIX Swiss Exchange Ticker
HBMN
Key Figures
| as at 15 May 2012 | CHF |
| NAV per share | 58.98 |
| Net assets | 533 Mio. |
© HBM BioVentures Ltd